Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADZENYS XR-ODT in preschool children with ADHD
NCT07169162Phase 4Withdrawn
- Sponsor
- Aytu BioPharma
- Start
- May 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Amphetamine XR-ODT in attention deficit hyperactivity disorder (ADHD), sponsored by Aytu BioPharma. Planned start May 2019; status: withdrawn.
02
Drugs
Amphetamine XR-ODT
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07169162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169162.